Gene therapy

Acta Urologica Japonica

Volumn 51, Issue 2, 2005, Pages 75-79

  Gotoh, Akinobu ^a   Shirakawa, Toshiro ^a   Wada, Yoshitaka ^b   Hinata, Nobuyuki ^b   Terao, Shuji ^b   Hara, Isao ^b   Arakawa, Soichi ^b   Kamidono, Sadao ^b   Okada, Hiroshi ^c   Takenaka, Atsushi ^d   Fujisawa, Masato ^d  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Gene therapy; Hormone refractory; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; OSTEOCALCIN;

ARTICLE; BONE METASTASIS; GENE THERAPY; HUMAN; PROSTATE CANCER; RECURRENT DISEASE; SAFETY;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; FORECASTING; GENE THERAPY; GENETIC VECTORS; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; ORGAN SPECIFICITY; OSTEOCALCIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 20144365010     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ko SC, Cheon J, Kao C, et al. : Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 56: 4614-4619, 1996
2. Gotoh A, Ko SC, Shirakawa T, et al. : Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 160: 220-229, 1998
3. Shirakawa T, Gotoh A, Wada Y, et al. : Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol 4: 73-82, 2000
4. Cheon J, Ko SC, Gardner TA, et al. : Chemogene therapy : Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Therapy 4: 359-365, 1997
5. Shirakawa T, Ko SC, Gardner TA, et al. : In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene. Cancer Gene Therapy 5: 274-280, 1998
6. Koeneman KS, Kao C, Ko SC, et al. : Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18: 102-110, 2000
7. Kubo H, Gardner TA, Wada Y et al. : Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14: 227-241, 2003
8. Moolten FL and Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82 : 297-300, 1990
9. Desbois C, Hogue DA and Karsenty G : The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chem 269: 1183-1190, 1994
10. Gotoh A, Shirakawa T, Wada Y, et al. : Frontiers in human genetics : diseases and technologies ; gene therapy for prostate cancer ; development of tissue specific promoter-based gene therapy. pp 363-376 World Scientific Publ, Singapore, 2001